Metabolic syndrome as an independent predictor of response and survival in locally advanced gastric cancer treated with neoadjuvant immunochemotherapy

Cancer research · Esophageal cancer

MetS was independently associated with higher pCR.

Metabolic syndrome (MetS) is prevalent in gastric cancer patients. The obesity paradox, where metabolic excess is associated with improved outcomes in patients receiving immune checkpoint inhibitor (ICI) therapy, remains uninvestigated in locally advanced gastric cancer (LAGC) treated with neoadjuvant immunochemotherapy. We evaluated MetS as a dual predictor of pathological response, immune‑related adverse events (irAEs), disease‑free survival (DFS), and overall survival (OS). MetS was independently associated with higher pathological complete response (pCR) and major pathological response (MPR) and was a favorable prognostic factor for DFS and OS without increasing immunotherapy toxicity.

Demonstrates that metabolic syndrome can act as a biomarker to predict better therapeutic outcomes and survival in patients undergoing neoadjuvant immunochemotherapy for locally advanced gastric cancer.

Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.

Original source

Related signals